Mersana Therapeutics, Inc. (MRSN) Financial Statements (2024 and earlier)

Company Profile

Business Address 840 MEMORIAL DRIVE
CAMBRIDGE, MA 02139
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

12/31/2023
Q4
9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments186,283128,732122,825128,885184,082135,338
Cash and cash equivalents186,283128,732122,825128,885184,082135,338
Receivables    30,000  
Other undisclosed current assets63,455168,355158,982160,334115,955101,741
Total current assets:249,738297,087281,807319,219300,037237,079
Noncurrent Assets
Operating lease, right-of-use asset8,4239,1309,80610,47511,06111,694
Property, plant and equipment    3,985  
Restricted cash and investments 478478478 478478
Other noncurrent assets478517588661616724
Other undisclosed noncurrent assets3,7873,7883,516 2,6582,376
Total noncurrent assets:13,16613,91314,38815,12114,81315,272
TOTAL ASSETS:262,904311,000296,195334,340314,850252,351
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities42,26750,38650,74457,13564,01948,268
Employee-related liabilities9,0835,854
Accounts payable12,94616,91818,15613,95113,7328,158
Accrued liabilities29,32133,46832,58843,18441,20434,256
Deferred revenue21,59220,50028,76930,61030,92426,230
Debt   240  
Other liabilities9371,009985990237234
Other undisclosed current liabilities3,1373,0252,9042,558(6,386)(3,262)
Total current liabilities:67,93374,92083,40291,53388,79471,470
Noncurrent Liabilities
Long-term debt and lease obligation25,00025,00025,00024,92934,29135,058
Long-term debt, excluding current maturities25,00025,00025,00024,92925,00025,000
Liabilities, other than long-term debt117,621121,200123,495125,821101,68312,012
Deferred revenue111,504114,197115,582117,043101,41711,684
Other liabilities6776140203266328
Operating lease, liability6,0506,9277,7738,5759,29110,058
Other undisclosed noncurrent liabilities 155804 (147)(223)
Total noncurrent liabilities:142,776146,280148,499150,750135,82746,847
Total liabilities:210,709221,200231,901242,283224,621118,317
Equity
Equity, attributable to parent52,19589,80064,29492,05790,229134,034
Common stock121211111010
Additional paid in capital858,999854,998775,125746,889700,217684,106
Accumulated other comprehensive income (loss)1(49)12(152)(231)(126)
Accumulated deficit(806,817)(765,161)(710,854)(654,691)(609,767)(549,956)
Total equity:52,19589,80064,29492,05790,229134,034
TOTAL LIABILITIES AND EQUITY:262,904311,000296,195334,340314,850252,351

Income Statement (P&L) ($ in thousands)

12/31/2023
Q4
9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
Revenues7,69810,6547,80214,6885,5734,284
Gross profit:7,69810,6547,80214,6885,5734,284
Operating expenses(51,639)(67,155)(65,603)(60,514)(65,212)(56,034)
Operating loss:(43,941)(56,501)(57,801)(45,826)(59,639)(51,750)
Nonoperating income (expense)2,2852,1941,638902(172)(469)
Investment income, nonoperating3,3023,2192,6211,866708291
Interest and debt expense(1,017)(1,025)(983)(964)(880)(760)
Loss from continuing operations:(42,673)(55,332)(57,146)(45,888)(60,691)(52,979)
Loss before gain (loss) on sale of properties:(60,691)(52,979)
Other undisclosed net income  983964  
Net loss:(42,673)(55,332)(56,163)(44,924)(60,691)(52,979)
Other undisclosed net income attributable to parent 1,0171,025  880760
Net loss available to common stockholders, diluted:(41,656)(54,307)(56,163)(44,924)(59,811)(52,219)

Comprehensive Income ($ in thousands)

12/31/2023
Q4
9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
Net loss:(42,673)(55,332)(56,163)(44,924)(60,691)(52,979)
Other comprehensive income (loss)   164  (126)
Other undisclosed comprehensive loss    (152)  
Comprehensive loss:(42,673)(55,332)(55,999)(45,076)(60,691)(53,105)
Other undisclosed comprehensive income, net of tax, attributable to parent1,067964 231775760
Comprehensive loss, net of tax, attributable to parent:(41,606)(54,368)(55,999)(44,845)(59,916)(52,345)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: